Inventiva S.A. (IVEVF)
Inventiva S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Daix, BF, FR. The stock last traded at $3.59, up 0.00% on the session, giving a market capitalisation of $848.0M. On trailing twelve-month figures it carries a trailing P/E of -2.17, a net margin of -7899.6%. Its beta of 0.91 implies it has historically moved less than the broad market.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other diseases. Its leading drug candidate, Lanifibranor, has successfully completed Phase IIb clinical trials for NASH treatment. The company is also advancing Odiparcil, which has concluded Phase IIa clinical investigation for addressing MPS VI subtype disease. Furthermore, Inventiva maintains a pipeline of earlier-stage programs targeting oncology and other therapeutic areas. The firm has established strategic collaborations, including one with AbbVie for autoimmune diseases and another with Boehringer Ingelheim International GmbH to develop novel treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is headquartered in Daix, France.
Inventiva S.A. is most often compared with the following Healthcare names: